Sanofi-Aventis (France)'s Multaq to get U.S. Panel Review in March ...
PARIS, Nov 27 (Reuters) - Sanofi-Aventis' experimental heart drug Multaq will be reviewed by an independent expert panel in the United States next March, ...
http://www.biospace.com/news_story.aspx?StoryID=118944&full=...
|
Further Analysis From ATHENA Study Showed That Multaq(R ...
This analysis showed that Multaq(R) (dronedarone) decreased the risk of stroke by 34% in patient with atrial fibrillation or atrial flutter already ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of ...
24 Oct 2008 ... New post-hoc analysis from ATHENA Study showed that Multaq® on top of standard therapy significantly decreased the total number of hospital ...
http://biz.yahoo.com/prnews/081111/ny45224.html?.v=1...
|
Sanofi-Aventis (France) Release: Dronedarone (Multaq(R)) Reduced ...
11 Nov 2008 ... PA) Release: Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation; Study Meets ...
http://www.biospace.com/news_story.aspx?NewsEntityId=116948...
|
BioPortfolio - Multaq
Matching: drug arrhythm athena multaq sanofi atrial stroke ... Sanofi-aventis potential blockbuster Multaq (dronedarone) has been shown to reduce the risk .
...
http://www.bioportfolio.com/search/Multaq.html...
|
Landmark ATHENA Study Findings With Multaq®(dronedarone) Show 24 ...
15 May 2008 ... For the first time in twenty years of clinical drug trials in atrial fibrillation, an investigational medicine, Multaq®, ...
http://www.prnewswire.com/mnr/sanofiaventis/33333/...
|
Sanofi-Aventis (France)'s Multaq(R) Granted FDA Priority Review ...
8 Aug 2008 ... "We are pleased that the FDA has designated Multaq® for priority review," said Marc Cluzel, sanofi-aventis Senior Vice President, ...
http://www.biospace.com/news_story.aspx?NewsEntityId=106284...
|
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows ...
For the first time in twenty years of clinical drug trials in atrial fibrillation, an investigational medicine, Multaq(R), showed a significant
decrease in ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted ...
The most frequently reported adverse events of Multaq(R) vs. placebo in the ATHENA trial were gastro-intestinal effects (26% vs. 22%), skin disorders (10%
...
http://www.biospace.com/news_story.aspx?NewsEntityId=97672...
|
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of ...
New post-hoc analysis from ATHENA Study showed that Multaq(R) on top of standard therapy significantly decreased the total number of hospital days by 28% in ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=...
|
